XtalPi Acquires Liverpool ChiroChem, Expanding Chemical Discovery
Deal News | Jun 13, 2025 | PR Newswire Cision XtalPi Inc.
XtalPi, an innovative R&D platform integrating quantum physics, AI, and robotics, has acquired Liverpool ChiroChem (LCC), a leader in chiral chemistry technology. This acquisition is poised to significantly advance XtalPi's capabilities in chemical space exploration, leveraging LCC's expertise in automated chiral molecule design and synthesis. XtalPi, known for its advanced R&D platform, seeks to enhance its ability to innovate in pharmaceuticals, materials, agriculture, and specialty chemicals with this strategic merger. The combined entity aims to expand chemical discovery, offering cutting-edge solutions through a global network of labs and AI infrastructure across the US, Europe, and Asia. Both companies will unite efforts to elevate their predictive algorithms and high-precision automation capabilities, facilitating the discovery of novel therapeutics with increased efficiency.
Sectors
- Pharmaceutical
- Chemicals
- R&D/Technology
Geography
- United States – XtalPi, a US-based company, extends its technological capabilities through this acquisition.
- United Kingdom – LCC, based in Liverpool, UK, is key to the acquisition, enhancing transatlantic capabilities and collaboration in chemical space exploration.
- Europe – The acquisition strengthens XtalPi's presence in European markets with regional labs and operations.
- Asia – Both companies have a global reach with operations extending into Asia, emphasizing international collaboration.
Industry
- Pharmaceutical – The acquisition enhances drug discovery and development capabilities by combining XtalPi's AI and robotics technologies with LCC's chiral chemistry expertise.
- Chemicals – The merger aligns with chemical sector interests by expanding the capabilities for novel materials and specialty chemical applications.
- R&D/Technology – The integration of AI, quantum physics, and automated platforms in chemical research highlights the importance of technology in advancing R&D processes.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| XtalPi Inc. | Acquirer | Company | A leading R&D platform powered by quantum physics, AI, and robotics, focused on drug discovery and materials science. |
| Liverpool ChiroChem (LCC) | Target Company | Company | A pioneer in automated chiral chemistry technologies, supporting small molecule drug discovery and novel chemical developments. |
| Xuekun Shi | Chief Operating Officer | Person | COO of XtalPi, overseeing the integration of LCC's technologies into XtalPi's AI-driven platform. |
| Paul Colbon | Chief Executive Officer | Person | CEO of LCC, continuing to lead and guide the collaboration following the acquisition. |